Over 74,000 people were kicked out of clinical trials because of Trump cuts

A recent study has revealed that the abrupt cessation of federal funding for biomedical research by the Trump administration has had a profound impact on ongoing clinical trials. According to findings published in JAMA Internal Medicine, at least 383 clinical trials were cancelled, leaving more than 74,000 participants without access to vital experimental treatments, monitoring, or follow-ups. Conducted by researchers at Harvard, the study highlights the significant implications of the funding cuts, illustrating not only the inefficiency and wastefulness of such decisions but also the ethical dilemmas they create. In March, the National Institutes of Health (NIH) announced a staggering $1.8 billion in grant funding cuts that were deemed inconsistent with the administration's priorities. The research team, led by health care policy expert Anupam Jena, utilized an NIH database along with a federal accountability tracking tool to analyze grants supporting clinical trials that were active as of February 28 but ultimately terminated by August 15. Within that timeframe, there were 11,008 trials funded at various stages, of which 383 were halted. The cancelled trials varied in their progress, with 14 percent still in early phases before participant recruitment, while 34.5 percent were in the recruitment stage. A small fraction, 3.4 percent, was enrolling participants by invitation, and 36 percent had already been completed. Additionally, 43 trials were active but no longer recruiting, involving 74,311 participants who were in the midst of receiving interventions. Breaking down the focus areas of the cancelled trials reveals a concerning trend: 31 percent were related to cancer research, 25 percent to infectious diseases, while reproductive health and mental health trials accounted for 12.5 percent and 12 percent, respectively. This significant disruption raises questions about the future of clinical research and the ethical responsibilities of funding agencies.